Analysts See $-1.02 EPS for Radius Health, Inc. (RDUS) as of May, 9

Radius Health, Inc. (NASDAQ:RDUS) Corporate Logo
During 2018 Q4 the big money sentiment decreased to 1.14. That’s change of 0.26, from 2018Q3’s 1.4. 19 investors sold all, 30 reduced holdings as Radius Health, Inc. ratio is negative. 36 increased stakes while 20 funds took stakes. Funds hold 42.17 million shares thus 10.64% less from 2018Q3’s 47.19 million shares.
Wellington Management Llp owns 3.59M shs for 0.01% of their capital. Deutsche Bancorporation Ag has invested 0.01% in Radius Health, Inc. (NASDAQ:RDUS). Knott David M holds 0.6% or 77,269 shs. Blackrock invested in 0% or 3.31M shs. Metropolitan Life Ins Co New York has 0% invested in Radius Health, Inc. (NASDAQ:RDUS). Weiss Multi invested 0.01% of its capital in Radius Health, Inc. (NASDAQ:RDUS). Price T Rowe Md accumulated 2.54 million shs or 0.01% of the stock. United Service Automobile Association owns 45,119 shs for 0% of their capital. Pictet Asset Mngmt owns 161,700 shs. Tower Capital (Trc) stated it has 39 shs. American Group Inc reported 26,642 shs. Pura Vida Investments Lc accumulated 57,131 shs or 0.59% of the stock. C Worldwide Group Inc Hldg A S stated it has 0% in Radius Health, Inc. (NASDAQ:RDUS). Parametric Portfolio stated it has 27,602 shs. Tiaa Cref Invest Mgmt Limited Liability Co holds 0% or 255,199 shs.

Radius Health, Inc. registered $2.10 million net activity with 4 insider buys and 0 sales since December 14, 2018. On Tuesday, March 5 $246,190 worth of Radius Health, Inc. (NASDAQ:RDUS) was bought by Hopfield Jessica. 3,000 shs valued at $47,130 were bought by Kelly Joseph Francis on Monday, December 17.

Radius Health, Inc. (NASDAQ:RDUS)’s earnings report is anticipated on May, 9., Zacks reports. Analysts forecast $-1.02 EPS, which is $0.35 up or 25.55 % from 2018’s $-1.37 EPS. Analysts at Wall Street see Radius Health, Inc.’s 13.33 % negative EPS growth compared to $-0.90 EPS for last quarter. RDUS is touching $22 during the last trading session, after increased 0.82%.Radius Health, Inc. has volume of 495,668 shares. Since April 16, 2018 RDUS has declined 46.96% and is downtrending. RDUS underperformed by 51.33% the S&P 500.

Radius Health, Inc. (NASDAQ:RDUS) Ratings Coverage

In total 2 analysts cover Radius Health (NASDAQ:RDUS). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. (NASDAQ:RDUS) has 50% bullish analysts. 3 are the (NASDAQ:RDUS)’s ratings reports on Apr 16, 2019 according to StockzIntelligence Inc. On Friday, March 1 the firm earned “Hold” rating by H.C. Wainwright. On Friday, November 2 the firm has “Overweight” rating by JP Morgan given.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States.The firm is worth $1.01 billion. The Company’s product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch.Currently it has negative earnings. The firm is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer.

For more Radius Health, Inc. (NASDAQ:RDUS) news announced briefly go to: Nasdaq.com, Streetinsider.com, Seekingalpha.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Why Is Radius Health (RDUS) Down 9.7% Since its Last Earnings Report? – Nasdaq” announced on June 11, 2018, “Radius Health (RDUS) Reports Analysis from Phase 3 ACTIVE Trial & Data from Preclinical Studies for TYMLOS – StreetInsider.com” on March 25, 2019, “Radius Health beats by $0.43, beats on revenue – Seeking Alpha” with a publish date: November 01, 2018, “Radius Health Q4 2018 Earnings Preview – Seeking Alpha” and the last “Radius Health to Present Data on TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting – GlobeNewswire” with publication date: March 18, 2019.

Radius Health, Inc. (NASDAQ:RDUS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.